<DOC>
	<DOCNO>NCT00418002</DOCNO>
	<brief_summary>The purpose study assess safety tolerability AQW051 administer single multiple dos elderly healthy volunteer . In addition , pharmacokinetic effect assess possible effect cognition .</brief_summary>
	<brief_title>Safety Tolerability AQW051 Elderly Healthy Volunteers .</brief_title>
	<detailed_description />
	<criteria>Healthy male postmenopausal female subject 60 80 year age good health determine past medical history . Postmenopausal woman must regular menstrual bleeding least 1 year prior inclusion . Male subject must use doublebarrier local contraception . Body mass index must within range 18 33 . Subjects must weigh least 50 kg participate study . The regular intake concomitant drug include thyroxine , paracetamol , low dose nonsteroidal antiinflammatory drug , lipid lower drug , vitamin dietary supplement without caffeine nicotinic acid , hormone replacement therapy allow , stable treatment least 3 month . Intake nutritional supplement ( e.g . omega3 , vitamin , mineral , codliver oil ) allow . Able communicate well investigator , understand comply requirement study . Understand sign write informed consent . Smokers ( use tobacco product previous 3 month ) . Use prescription drug within 4 week prior dose , overthecounter medication ( e.g . herbal supplement ) within 2 week prior study start except note previously Use central nervous system active drug anticholinergic drug previous 3 month use drug treatment know cause major organ system toxicity previous 3 month prohibit . A past personal close family medical history clinically significant cardiac abnormality . Current diagnosis cardiac arrhythmia derive ECG and/or Holter ECG . Current diagnosis cardiovascular disease . Current diagnosis history autonomic dysfunction ( e.g . history fainting , orthostatic hypotension , sinus arrhythmia ) . History Acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease ) Clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) Known hypersensitivity severe adverse event darifenacin similar drug Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize participation study Immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . Drug alcohol abuse within 12 month prior dose . Diagnosis cognitive impairment ( Mini Mental State Exam &lt; 27 ) . History current diagnosis cerebrovascular disease ( e.g. , stroke , transient ischemic attack , aneurysm ) . Current DSMIV diagnosis major depression and/or DSMIV Axis 1 diagnosis may interfere evaluation patient â€™ response study medication , include primary neurodegenerative dementia , schizophrenia , bipolar disorder . History current diagnosis active , uncontrolled seizure disorder . History head injury neurological disorder .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Single-rising dose , multiple rise dose , elderly , cognitive , , pharmacokinetic , impairment .</keyword>
	<keyword>Healthy elderly male female subject</keyword>
</DOC>